Laura Iaffaldano
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
HLA-Haploidentical Anti-CD7 Chimeric Antigen Receptor (CAR) T Cells for Transplant-Naïve Patients With Refractory T-Cell Acute Lymphoblastic Leukemia.
Journal: American journal of hematology
Published: July 08, 2026
Dinutuximab beta with TEMIRI chemotherapy in relapsed/refractory neuroblastoma: Real-world insights into the open question of GD2 expression.
Journal: Translational oncology
Published: May 18, 2026
CD19 antigen: from tumor target to safety switch in CAR-T cell therapy.
Journal: Haematologica
Published: April 07, 2026
Publisher Correction: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: September 09, 2025
GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial.
Journal: Nature medicine
Published: March 01, 2025
Point-of-care fresh CAR T cells for pediatric or young adult BCP-ALL that is relapsed/refractory or in very-high-risk first relapse.
Journal: Blood advances
Published: February 10, 2025
Truncated form of human CD19 antigen as a suicide gene to control T-cell alloreactivity: ΔCD19.
Journal: Haematologica
Published: January 13, 2025
Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.
Journal: Journal of hematology & oncology
Published: July 11, 2024
Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma.
Journal: Nature medicine
Published: February 09, 2024
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 21, 2023
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Journal: The New England journal of medicine
Published: April 05, 2023
Last Updated: 09/26/2026